Securian Asset Management Inc. Decreases Stock Position in Pfizer Inc. $PFE

Securian Asset Management Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 274,579 shares of the biopharmaceutical company’s stock after selling 22,669 shares during the period. Securian Asset Management Inc.’s holdings in Pfizer were worth $6,996,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Vanguard Group Inc. grew its position in Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after buying an additional 1,820,634 shares during the last quarter. Norges Bank acquired a new position in shares of Pfizer in the 2nd quarter valued at $2,270,157,000. Charles Schwab Investment Management Inc. raised its stake in Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after acquiring an additional 1,135,457 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its position in Pfizer by 2.0% during the 2nd quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock worth $1,172,980,000 after acquiring an additional 950,239 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. UBS Group set a $25.00 price objective on shares of Pfizer in a research note on Tuesday. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $27.88.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a multi‑year collaboration with Cartography Biosciences to discover tumor‑selective antigens, which could expand its oncology pipeline and add future revenue/catalysts. Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor‑Selective Antigens
• Positive Sentiment: Coverage noting Pfizer’s discounted valuation and recent M&A (Seagen) highlights potential upside if the company executes on oncology and obesity programs — supports the argument that the stock is attractively priced for value/dividend investors. These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
• Neutral Sentiment: Analysts and retail investors are giving PFE attention for its dividend yield and recent price weakness — this interest can stabilize flows but isn’t an earnings catalyst by itself. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Pfizer is included in dividend and income‑focused writeups comparing it to peers (e.g., Ford), which may maintain demand from yield‑seeking investors but won’t move fundamentals. Better Dividend Stock: Ford vs. Pfizer
• Neutral Sentiment: Reports that Pfizer plans modest price increases across a number of medicines could lift revenue modestly, but political/PR risk around drug pricing remains a balancing factor. Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals
• Neutral Sentiment: Pfizer invited the public to its JP Morgan Healthcare Conference webcast (CEO Bourla), which could provide guidance clarity or program updates — a potential short‑term catalyst if management gives new detail. Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Negative Sentiment: UBS initiated a Hold on PFE citing a patent‑cliff overhang and an uncertain pipeline that offsets obesity program upside — a formal downgrade/hold stance can weigh on sentiment. Patent Cliff Overhang and Uncertain Pipeline Offset Obesity Upside, Justifying Hold on Fairly Valued Pfizer Shares
• Negative Sentiment: Analysis of Pfizer’s 2026 guidance warns continued margin pressure and slower growth into 2026, which supports cautious positioning by investors. Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure
• Negative Sentiment: Analyst previews ahead of Q4 flag an expected low double‑digit profit decline, which reinforces the near‑term earnings risk profile. Pfizer’s Quarterly Earnings Preview: What You Need to Know

Pfizer Price Performance

Shares of NYSE PFE opened at $25.44 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market capitalization of $144.63 billion, a price-to-earnings ratio of 14.79 and a beta of 0.47. The firm’s 50 day simple moving average is $25.21 and its 200-day simple moving average is $24.94. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.